Megetra 160mg Tablet contains Megestrol acetate, a synthetic progestin used primarily for its antineoplastic and appetite-stimulating properties. It is indicated for the management of anorexia, cachexia, or significant weight loss in patients with advanced cancer or acquired immunodeficiency syndrome (AIDS). Megestrol acts by modulating the hypothalamic appetite control centers, thereby enhancing appetite and promoting weight gain. Additionally, it exhibits antitumor activity in hormone-responsive cancers such as breast and endometrial carcinoma by exerting progestational effects that inhibit tumor growth. Megetra should be administered orally as prescribed by a healthcare professional, with dosage tailored to the patient’s clinical condition and response. Common side effects may include weight gain, edema, thromboembolic events, and gastrointestinal disturbances. Caution is advised in patients with a history of thromboembolism, cardiovascular disease, or hepatic impairment. Regular monitoring of blood pressure, liver function, and coagulation parameters is recommended during therapy. Megetra is contraindicated in pregnancy and in patients with known hypersensitivity to megestrol or any component of the formulation. This medication should be used under strict medical supervision to optimize therapeutic outcomes and minimize potential adverse effects.